Please assess the completion status of the following clinical trial:

Trial Title: Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion~* MDS classified by hematopathology review as WHO categories refractory anemia (RA) or refractory cytopenia with multi-lineage dysplasia (RCMD) or refractory anemia with ring sideroblasts (RARS) or refractory anemia with excess blasts (RAEB1 or RAEB2) or chronic myelo-monocytic leukemia (CMML1 or CMML2)~* Symptomatic anemia OR thrombocytopenia with a platelet count of \< 100 x 10\^9/L OR transfusion dependence for red-cells OR transfusion dependence for platelets OR absolute neutrophil count \< 1 x 10\^9/L~Exclusion~* MDS of the WHO sub-types RA or RCMD with sole 5q- abnormality on cytogenetics unless failed lenalidomide (Revlimid) therapy~* Previous treatment with decitabine~* Untreated erythropoietin deficiency defined as an erythropoietin level of \< 200 IU/L and erythropoietin replacement therapy for \< 8 weeks (erythropoietin deficiency until corrected)~* Uncontrolled infection~* Severe sepsis or septic shock~* Current pregnancy or breast feeding~* The patient is of childbearing age, and is unwilling to use contraception and has not had a tubal ligation, hysterectomy, or vasectomy , or their partner is also unwilling to use an acceptable method of contraception as determined by the investigator~* Not able to give informed consent~* Altered mental status or seizure disorder~* ALT \> 300 IU; or albumin \< 2.0 mg/dL~* Creatinine \> 2.5 mg/dl and creatinine clearance \< 60ml/min~* B12, folate, or iron deficient, until corrected~* NYHA class III/IV status~* ECOG performance status \> 2~* HIV positive or history of seropositivity for HIV~* Transformation to acute leukemia ( \>= 20% myelo-blasts in marrow aspirate)~* Any experimental agents other than the study drug decitabine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I: decitabine (Type: EXPERIMENTAL): INDUCTION PHASE: Patients receive decitabine subcutaneously (SQ) twice weekly for 4 weeks or thrice weekly until achieving bone marrow blasts \&lt; 5%. MAINTENANCE PHASE: Patients then receive decitabine SQ twice weekly for up to 52 weeks in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).